Literature DB >> 19092780

Pharmacokinetic considerations for new targeted therapies.

S D Baker1, S Hu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19092780      PMCID： PMC2628961          DOI： 10.1038/clpt.2008.242

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  25 in total

1.  Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

Authors:  Jian-Feng Lu; Steve M Eppler; Julie Wolf; Marta Hamilton; Ashok Rakhit; Rene Bruno; Bert L Lum
Journal:  Clin Pharmacol Ther       Date:  2006-08       Impact factor: 6.875

2.  Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.

Authors:  Erin R Gardner; Herman Burger; Ron H van Schaik; Allan T van Oosterom; Ernst A de Bruijn; Gunther Guetens; Hans Prenen; Floris A de Jong; Sharyn D Baker; Susan E Bates; William D Figg; Jaap Verweij; Alex Sparreboom; Kees Nooter
Journal:  Clin Pharmacol Ther       Date:  2006-08       Impact factor: 6.875

3.  CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.

Authors:  Jing Li; Mats O Karlsson; Julie Brahmer; Avery Spitz; Ming Zhao; Manuel Hidalgo; Sharyn D Baker
Journal:  J Natl Cancer Inst       Date:  2006-12-06       Impact factor: 13.506

4.  Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.

Authors:  George Cusatis; Vanesa Gregorc; Jing Li; Anna Spreafico; Roxann G Ingersoll; Jaap Verweij; Vienna Ludovini; Eugenio Villa; Manuel Hidalgo; Alex Sparreboom; Sharyn D Baker
Journal:  J Natl Cancer Inst       Date:  2006-12-06       Impact factor: 13.506

5.  Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.

Authors:  Jing Li; Julie Brahmer; Wells Messersmith; Manuel Hidalgo; Sharyn D Baker
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

6.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

7.  Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

Authors:  Jayesh Desai; Leila Yassa; Ellen Marqusee; Suzanne George; Mary C Frates; Ming Hui Chen; Jeffrey A Morgan; Samuel S Dychter; P Reed Larsen; George D Demetri; Erik K Alexander
Journal:  Ann Intern Med       Date:  2006-11-07       Impact factor: 25.391

8.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Authors:  Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force
Journal:  Nat Med       Date:  2006-07-23       Impact factor: 53.440

9.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

Review 10.  Sunitinib in the management of gastrointestinal stromal tumours (GISTs).

Authors:  T G Hopkins; M Marples; D Stark
Journal:  Eur J Surg Oncol       Date:  2007-12-21       Impact factor: 4.424
View more
  17 in total

Review 1.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

Review 2.  ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.

Authors:  Jiexin Deng; Jie Shao; John S Markowitz; Guohua An
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

Review 3.  Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Authors:  Michelle A Rudek; Charles Flexner; Richard F Ambinder
Journal:  Lancet Oncol       Date:  2011-05-12       Impact factor: 41.316

4.  Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.

Authors:  Mingqing Chen; Claudia Neul; Elke Schaeffeler; Franziska Frisch; Stefan Winter; Matthias Schwab; Hermann Koepsell; Shuiying Hu; Stefan Laufer; Sharyn D Baker; Alex Sparreboom; Anne T Nies
Journal:  Clin Pharmacol Ther       Date:  2019-09-03       Impact factor: 6.875

5.  Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.

Authors:  Brian D Furmanski; Shuiying Hu; Ken-Ichi Fujita; Lie Li; Alice A Gibson; Laura J Janke; Richard T Williams; John D Schuetz; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2013-06-21       Impact factor: 12.531

Review 6.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

7.  Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma.

Authors:  Qiang Fu; Mingqing Chen; Shuiying Hu; Craig A McElroy; Ron H Mathijssen; Alex Sparreboom; Sharyn D Baker
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-05-05       Impact factor: 3.205

8.  Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.

Authors:  Shuiying Hu; Zhaoyuan Chen; Ryan Franke; Shelley Orwick; Ming Zhao; Michelle A Rudek; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

9.  Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.

Authors:  Eric I Zimmerman; Shuiying Hu; Justin L Roberts; Alice A Gibson; Shelley J Orwick; Lie Li; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2013-01-22       Impact factor: 12.531

10.  Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.

Authors:  Venkateswaran C Pillai; Raman Venkataramanan; Robert A Parise; Susan M Christner; Roberto Gramignoli; Stephen C Strom; Michelle A Rudek; Jan H Beumer
Journal:  Drug Metab Dispos       Date:  2013-08-02       Impact factor: 3.922
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.